Is Pyxis Oncology, Inc. (PYXS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 23.7% / 30% | 148.8% / 30% | 0.0% / 30% | 43.6% / 5% | ✗ NOT HALAL |
| DJIM | 23.7% / 33% | 148.8% / 33% | 0.0% / 33% | 43.6% / 5% | ✗ NOT HALAL |
| MSCI | 12.9% / 33% | 80.8% / 33% | 0.0% / 33% | 43.6% / 5% | ✗ NOT HALAL |
| S&P | 23.7% / 33% | 148.8% / 33% | 0.0% / 33% | 43.6% / 5% | ✗ NOT HALAL |
| FTSE | 12.9% / 33% | 80.8% / 33% | 0.0% / 50% | 43.6% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.8% | |
| Operating Margin | -159.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -91.4% | |
| Return on Assets (ROA) | -41.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$58M |
| Free Cash Flow | -$58M |
| Total Debt | $20M |
| Debt-to-Equity | 35.0 |
| Current Ratio | 3.4 |
| Total Assets | $157M |
Price & Trading
| Last Close | $1.39 |
| 50-Day MA | $1.50 |
| 200-Day MA | $2.11 |
| Avg Volume | 828K |
| Beta | 1.5 |
|
52-Week Range
$0.83
| |
About Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pyxis Oncology, Inc. (PYXS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pyxis Oncology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pyxis Oncology, Inc.'s debt ratio?
Pyxis Oncology, Inc.'s debt ratio is 23.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.9%.
What are Pyxis Oncology, Inc.'s key financial metrics?
Pyxis Oncology, Inc. has a market capitalization of $82M, and revenue of $16M. Return on equity stands at -91.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.